Piramal Builds GI Play With OTC Acquisitions

Piramal Enterprises' consumer products unit has acquired five brands from Organon India Pvt Ltd and MSD BV for INR920m ($13.8m), as it expands its offering in the fast growing gastrointestinals segment in India.

Piramal Enterprises' consumer products unit has acquired five brands from Organon India Pvt Ltd and MSD BV for INR920m ($13.8m), as it expands its offering in the fast growing gastrointestinals segment in India.

More from Alimentary/Metabolic

More from Therapy Areas

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By 

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By 

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.